- Investing Ideas
- /
- Australian Biotech Stocks
Australian Biotech Stocks
Results
41
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
41 companies
CSL
Market Cap: AU$95.8b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$197.99
7D
-0.2%
1Y
-32.0%
Telix Pharmaceuticals
Market Cap: AU$5.2b
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
TLX
AU$15.38
7D
12.6%
1Y
-25.9%
Mesoblast
Market Cap: AU$3.2b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.49
7D
6.0%
1Y
128.4%
Neuren Pharmaceuticals
Market Cap: AU$2.5b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$19.75
7D
-1.9%
1Y
37.6%
PYC Therapeutics
Market Cap: AU$586.2m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.01
7D
12.3%
1Y
-44.2%
Clinuvel Pharmaceuticals
Market Cap: AU$561.4m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$11.20
7D
-2.8%
1Y
-21.7%
Mayne Pharma Group
Market Cap: AU$416.8m
A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYX
AU$5.13
7D
3.0%
1Y
12.3%
Immutep
Market Cap: AU$374.3m
A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.26
7D
2.0%
1Y
-26.1%
Dimerix
Market Cap: AU$312.1m
A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.
DXB
AU$0.52
7D
-2.8%
1Y
33.3%
Botanix Pharmaceuticals
Market Cap: AU$294.2m
Operates as a commercial dermatology company in Australia and the United States.
BOT
AU$0.15
7D
20.0%
1Y
-60.5%
Aroa Biosurgery
Market Cap: AU$234.6m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.68
7D
-2.2%
1Y
21.4%
Vita Life Sciences
Market Cap: AU$136.3m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$2.44
7D
-4.7%
1Y
13.0%
LTR Pharma
Market Cap: AU$122.2m
A clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.
LTP
AU$0.68
7D
-5.6%
1Y
-60.9%
Alterity Therapeutics
Market Cap: AU$119.6m
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
ATH
AU$0.011
7D
0%
1Y
266.7%
Trajan Group Holdings
Market Cap: AU$112.9m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.74
7D
0%
1Y
-40.8%
EZZ Life Science Holdings
Market Cap: AU$104.3m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia.
EZZ
AU$2.21
7D
1.4%
1Y
-41.2%
Imugene
Market Cap: AU$81.4m
A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
IMU
AU$0.28
7D
-19.1%
1Y
-83.8%
Medical Developments International
Market Cap: AU$75.5m
Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.
MVP
AU$0.67
7D
-0.7%
1Y
55.8%
Radiopharm Theranostics
Market Cap: AU$68.6m
A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
RAD
AU$0.029
7D
-14.7%
1Y
-6.5%
Genetic Signatures
Market Cap: AU$60.2m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.27
7D
3.9%
1Y
-60.4%
NeuroScientific Biopharmaceuticals
Market Cap: AU$54.9m
Engages in the research and development of novel peptide-based pharmaceutical products.
NSB
AU$0.17
7D
0%
1Y
323.1%
Cynata Therapeutics
Market Cap: AU$48.7m
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
CYP
AU$0.20
7D
7.9%
1Y
-4.7%
Prescient Therapeutics
Market Cap: AU$44.2m
A clinical stage oncology company, develops drugs for the treatment of various cancers in Australia.
PTX
AU$0.042
7D
0%
1Y
7.7%
Vitura Health
Market Cap: AU$42.4m
Engages in the sale and distribution of medicinal cannabis products in Australia.
VIT
AU$0.064
7D
-1.5%
1Y
-15.8%
Syntara
Market Cap: AU$40.8m
Operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.
SNT
AU$0.025
7D
-3.8%
1Y
-30.6%
Little Green Pharma
Market Cap: AU$36.7m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.12
7D
-4.0%
1Y
33.3%
IDT Australia
Market Cap: AU$27.9m
Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the Unites States.
IDT
AU$0.065
7D
1.6%
1Y
-43.5%
Avecho Biotechnology
Market Cap: AU$22.2m
A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India.
AVE
AU$0.007
7D
0%
1Y
250.0%
Immuron
Market Cap: AU$20.4m
A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
IMC
AU$0.076
7D
1.3%
1Y
-27.6%
Althea Group Holdings
Market Cap: AU$16.9m
Manufactures, distributes, and sells cannabis-based medicines and recreational cannabis products in Australia, the United Kingdom, Canada, Germany, and Ireland.
AGH
AU$0.02
7D
-4.8%
1Y
-45.9%
Invex Therapeutics
Market Cap: AU$12.0m
A biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.
IXC
AU$0.16
7D
52.4%
1Y
116.2%
Percheron Therapeutics
Market Cap: AU$10.9m
Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.
PER
AU$0.01
7D
-9.1%
1Y
-90.0%
Chimeric Therapeutics
Market Cap: AU$9.8m
A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.
CHM
AU$0.003
7D
-25.0%
1Y
-78.6%
Invion
Market Cap: AU$9.4m
A clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.
IVX
AU$0.11
7D
-4.3%
1Y
-45.0%
ECS Botanics Holdings
Market Cap: AU$8.4m
Engages in the cultivation, manufacture, and sale of medicinal cannabis products in Australia and internationally.
ECS
AU$0.0065
7D
30.0%
1Y
-63.9%
Epsilon Healthcare
Market Cap: AU$7.2m
Operates as a healthcare and pharmaceuticals company primarily in Australia.
EPN
AU$0.024
7D
0%
1Y
20.0%